Mayo Clinic researchers conducted a study comparing the efficacy of multitarget stool DNA tests to fecal immunochemical testing for colorectal cancer screening in Alaska Native people. Here are six ...

Please provide your email address to receive an email when new articles are posted on . The multitarget stool DNA test had a positive predictive value of 31.4% for detecting advanced adenomas.

Stool-based DNA testing can help bridge CRC screening gaps between rural and urban populations by providing timely follow-up. The study found no significant difference in follow-up times for ...

Two noninvasive screening tests appeared to be effective in detecting colorectal cancer in an average-risk population, two trials suggested. In the BLUE-C trial, a next-generation multi-target stool ...

CT colonography reduced the incidence of colorectal cancer by up to 75% versus no screening, while stool DNA testing reduced the incidence by 59%. Stool testing was cost-effective relative to no ...

October 9, 2008 — Stool DNA testing is a new approach to screening for colorectal cancer, but it is an evolving technology. A study has found that the first-generation stool DNA test (SDT-1) is not ...

June 8, 2009 (Chicago, Illinois) – Detection of "long DNA" in the stool, when combined with fecal occult blood testing, detects colorectal cancers with a specificity of 90%. This approach is "among ...

Colon CT scans might be able to prevent more colon cancers than stool DNA testing Two CT screening approaches outperformed stool DNA testing in computer models CT screening also was more ...

A recent prospective cross-sectional study in Thailand demonstrates that multitarget stool DNA testing is highly sensitive and specific for detecting colorectal cancer (CRC) among Thai individuals.

Annual fecal immunochemical test-based surveillance could be as effective as colonoscopies in reducing long-term colorectal cancer incidence and mortality, according to a recent study published in ...

NEW YORK (Reuters Health) - A simplified colorectal cancer screening test that detects tumor DNA in stool is an improvement over an earlier-generation assay, according to North American researchers.

According to Cologuard, made by Wisconsin-based Exact Sciences, there are three primary reasons why you may receive a testing ...